Advice
in the absence of a submission from the holder of the marketing authorisation:
mepolizumab (Nucala®) is not recommended for use within NHSScotland.
Indication under review: As add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice614KB (PDF)
Medicine details
- Medicine name:
- mepolizumab (Nucala)
- SMC ID:
- SMC2488
- Indication:
As add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 May 2022